A new vaccine may one day delay the need to use ADT by harnessing patients’ immune systems, researchers reported at the 34th Annual Meeting & Preconference Programs of the Society for Immunotherapy of Cancer, or SITC 2019, which occurred in Maryland in November 2019. Read the article.
New Vaccine Could Delay ADT Use in Stage D0 Prostate Cancer Read More »
Cancer remains one of the world’s top healthcare challenges, but over the years our ability to treat the disease has dramatically improved. In fact, there is a sense that a new generation of therapies – and particularly those harnessing the power of the immune system – could dramatically extend expected survival and even effect long-term cures in patients. Read the article here.
Cancer immunotherapy: What’s on the horizon? Read More »
Researchers showed that a subset of men who had run out of all existing options for treatment survived much longer than expected when taking immunotherapy. Read the article here.
Major trial is first to show benefits of immunotherapy in some men with prostate cancer Read More »